Single Nucleotide Polymorphisms Associated with Prostate Cancer Progression: A Systematic Review.
Cancer Invest
; 42(1): 75-96, 2024 Jan.
Article
en En
| MEDLINE
| ID: mdl-38055319
ABSTRACT
BACKGROUND:
New biomarkers of progression in patients with prostate cancer (PCa) are needed to improve their classification and clinical management. This systematic review investigated the relationship between single nucleotide polymorphisms (SNPs) and PCa progression.METHODS:
A keyword search was performed in Pubmed, EMBASE, Scopus, Web of Science, and Cochrane for publications between 2007 and 2022. We included articles with adjusted and significant associations, a median follow-up greater than or equal to 24 months, patients taken to radical prostatectomy (RP) as a first therapeutic option, and results presented based on biochemical recurrence (BCR).RESULTS:
In the 27 articles selected, 73 SNPs were identified in 39 genes, organized in seven functional groups. Of these, 50 and 23 SNPs were significantly associated with a higher and lower risk of PCa progression, respectively. Likewise, four haplotypes were found to have a significant association with PCa progression.CONCLUSION:
This article highlights the importance of SNPs as potential markers of PCa progression and their possible functional relationship with some genes relevant to its development and progression. However, most variants were identified only in cohorts from two countries; no additional studies reproduce these findings.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Polimorfismo de Nucleótido Simple
Tipo de estudio:
Systematic_reviews
Idioma:
En
Revista:
Cancer Invest
Año:
2024
Tipo del documento:
Article